Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation


Non-cirrhotic portal vein thrombosis (ncPVT) most often occurs in the setting of intraabdominal proinflammatory processes. Less often, ncPVT may result from primary hematologic thrombophilia (most commonly JAK2V617F). Although these etiologic categories are pathophysiologically distinct, they are treated similarly using anticoagulation. We conducted a retrospective assessment of outcomes among ncPVT patients harboring JAK2V617F, and compared them to outcomes among patients with other etiologies for ncPVT, to determine whether anticoagulation alone is adequate therapy for JAK2V617F associated PVT. Outcomes were complete radiographic resolution (CRR) of PVT, recanalization (RC) of occlusive PVT, and development of significant portal hypertension (SPH). Three-hundred-thirty ncPVT patients seen between 1/2000 and 1/2019, including 37 harboring JAK2V617F (JAK2), 203 with other evident etiology (OE) for PVT, and 90 with no evident etiology (NE) for PVT followed for a median 29 months (53, 21, and 32 months respectively). Outcomes among the JAK2 cohort were dismal relative to the other groups. CRR rates were 8%, 31%, and 55% for the JAK2, NE, and OE cohorts respectively (multivariable HR JAK2:OE = 0.15 (0.05, 0.49), p = 0.0016). RC rates were 16%, 33%, and 49% for the JAK2, NE, and OE cohorts respectively (multivariable HR for RC JAK2:OE = 0.24 (0.09, 0.63), p = 0.0036). SPH rates were 49%, 32%, and 17% for the JAK2, NE, and OE cohorts respectively (multivariable HR for SPH JAK2:OE = 1.23 (0.62, 2.42), p = 0.5492). Given the strikingly poor outcomes among patients harboring JAK2V617F, anticoagulation alone does not appear to be adequate therapy for this cohort. Further investigation into thrombolysis and/or thrombectomy as an adjunct to anticoagulation is merited in this high-risk group.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. 1.

    Intagliata NM, Caldwell SH, Tripodi A (2019) Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 156(6):1582–1599

  2. 2.

    Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M et al (2009) JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617–5623

  3. 3.

    How J, Zhou A, Oh ST (2017) Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Ther Adv Hematol 8(3):107–118

  4. 4.

    Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R (2009) The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113(21):5246–5249

  5. 5.

    Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J et al (2010) Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 51(1):210–218

  6. 6.

    Klinger C, Riecken B, Schmidt A, De Gottardi A, Meier B, Bosch J et al (2017) Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. Dig Liver Dis 49(12):1345–1352

  7. 7.

    Brookmeyer R (1982) A confidence interval for the median survival time. Biometrics 38(1):29–41

  8. 8.

    Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I et al (2016) Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14(12):1572–1611

  9. 9.

    Iwakiri Y (2014) Pathophysiology of portal hypertension. Clin Liver Dis 18(2):281–291

  10. 10.

    Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91(2):169–175

  11. 11.

    Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L et al (2013) JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 122(23):3787–3797

  12. 12.

    Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J et al (2018) JAK2-V617F promotes venous thrombosis through beta1/beta2 integrin activation. J Clin Invest 128(10):4359–4371

  13. 13.

    Wang MQ, Guo LP, Lin HY, Liu FY, Duan F, Wang ZJ (2010) Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis. Cardiovasc Intervent Radiol 33(1):80–89

  14. 14.

    Malkowski P, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E et al (2003) Thrombolytic treatment of portal thrombosis. Hepatogastroenterology 50(54):2098–2100

  15. 15.

    Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF (2005) Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 16(5):651–661

  16. 16.

    Hall TC, Garcea G, Metcalfe M, Bilku D, Dennison AR (2011) Management of acute non-cirrhotic and non-malignant portal vein thrombosis: a systematic review. World J Surg 35(11):2510–2520

  17. 17.

    Turnes J, Garcia-Pagan JC, Gonzalez M, Aracil C, Calleja JL, Ripoll C et al (2008) Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 6(12):1412–1417

  18. 18.

    Sankar K, Stein BL (2018) Do all patients with polycythemia vera or essential thrombocythemia need cytoreduction? J Natl Compr Canc Netw 16(12):1539–1545

  19. 19.

    Finazzi G, De Stefano V, Barbui T (2018) Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J 8(7):64

Download references


The authors wish to acknowledge the support of the Biostatistics Shared Resource Facility, Icahn School of Medicine at Mount Sinai, and NCI Cancer Center Support Grant P30 CA196521-01.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Correspondence to Leonard Naymagon.

Ethics declarations

Conflict of interest

The authors have no relevant conflicts of interest to report.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors. This article describes a retrospective study which did require review of patient medical records. As such, this study was approved by the Program for the Protection of Human Subjects (PPHS) and the Institutional Review Board (IRB) of the Mount Sinai Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Naymagon, L., Tremblay, D., Zubizarreta, N. et al. Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02052-4

Download citation


  • Portal vein thrombosis (PVT)
  • Splanchnic vein thrombosis (SVT)
  • JAK2V617F
  • Myeloproliferative neoplasm (MPN)
  • Anticoagulation
  • Thrombectomy